{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:41Z","timestamp":1793119661133,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous leishmaniasis (CL) is a parasitic disease endemic to the Americas, with a high prevalence in Peru. In resource-limited settings where liposomal amphotericin B is often unavailable, amphotericin B deoxycholate (AmB-d) remains a second-line option. However, data on its safety and effectiveness in children are scarce. This study describes the clinical experience of 20 paediatric patients with CL treated with AmB-d in a referral centre in Peru.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective descriptive study of patients \u226414 years with confirmed localised CL who had failed parental sodium stibogluconate (Sb\n                      <jats:sup>5+<\/jats:sup>\n                      IM\/IV) treatment and received intravenous AmB-d at Hospital Cayetano Heredia (Peru) between January 2000 and December 2007. Patients received daily treatment until all lesions met the early cure criteria, defined as complete reepithelialization at the time of discharge. We collected demographic, clinical, and laboratory data, including the mean daily dose, cumulative dose, and adverse events (AEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 20 patients with a mean age of 4.9 years (\u00b13.7), and 90% had lesions on the face. Nineteen patients (95%) completed treatment and achieved early clinical cure. Mean cumulative dose was 19.8 mg\/kg (\u00b15.7) and mean treatment duration was 28.8 days (\u00b17.1). A total of 63.2% (12\/19) of patients achieved clinical cure with a cumulative dose below 20mg\/kg, and 84.2% with a dose below 25 mg\/kg. Systemic adverse events (AEs), including fever (90%) and anorexia (70%), occurred mainly between the second and third weeks of treatment (83%). Six patients (30%) developed an increase in serum creatinine and nine (45%) developed hypokalemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Intravenous amphotericin B deoxycholate (AmB-d) is an effective and well-tolerated second-line treatment for paediatric American CL unresponsive to Sb\n                      <jats:sup>5+<\/jats:sup>\n                      treatment. Despite the need for high cumulative doses, prolonged treatment durations, and frequent AEs, side effects were mild to moderate, transient, and did not lead to treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12344-w","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:47:54Z","timestamp":1766036874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dosing and safety of amphotericin B deoxycholate in paediatric American cutaneous leishmaniasis in Peru: a case series"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9914-5441","authenticated-orcid":false,"given":"Mercedes","family":"Sanchez-Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Verne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa Gonzales","family":"Lagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorela","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Llanos-Cuentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"6","key":"12344_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jaad.2014.08.051","volume":"73","author":"MZ Handler","year":"2015","unstructured":"Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: clinical perspectives. J Am Acad Dermatol. 2015;73(6):897\u2013908. quiz 909\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"12344_CR2","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, V\u00e9lez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671.","journal-title":"PLoS ONE"},{"key":"12344_CR3","first-page":"11","volume-title":"Leishmaniasis: epidemiological report for the Americas. No.13, December 2024","author":"Pan American Health Organization, Pan American Health Organization","year":"2024","unstructured":"Pan American Health Organization, Pan American Health Organization. Leishmaniasis: epidemiological report for the Americas. No.13, December 2024. Leishmaniases: Epidemiological Report of the Americas; 2024. p. 11."},{"key":"12344_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.actatropica.2017.09.028","volume":"177","author":"Y Hashiguchi","year":"2018","unstructured":"Hashiguchi Y, Gomez EAL, C\u00e1ceres AG, Velez LN, Villegas NV, Hashiguchi K, et al. Andean cutaneous leishmaniasis (Andean-CL, uta) in Peru and ecuador: the causative leishmania parasites and clinico-epidemiological features. Acta Trop. 2018;177:135\u201345.","journal-title":"Acta Trop"},{"key":"12344_CR5","doi-asserted-by":"crossref","unstructured":"Kato H, C\u00e1ceres AG, Seki C, Silupu Garc\u00eda CR, Holgu\u00edn Mauricci C, Castro Mart\u00ednez SC, et al. Further insight into the geographic distribution of leishmania species in Peru by cytochrome b and mannose phosphate isomerase gene analyses. PLoS Negl Trop Dis. 2019 June;13(6):e0007496.","DOI":"10.1371\/journal.pntd.0007496"},{"key":"12344_CR6","unstructured":"Llanos Cuentas EA. Risk factors associated with the transmission of Andean cutaneous leishmaniasis. [Internet] [doctoral]. London School of Hygiene & Tropical Medicine; 1994 [cited 2025 Feb 20]. Available from: https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/4654305\/."},{"issue":"1","key":"12344_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41182-021-00332-0","volume":"49","author":"JT Lana","year":"2021","unstructured":"Lana JT, Mallipudi A, Ortiz EJ, Arevalo JH, Llanos-Cuentas A, Pan WK. Risk factors for cutaneous leishmaniasis in a high-altitude forest region of Peru. Trop Med Health. 2021;49(1):40.","journal-title":"Trop Med Health"},{"key":"12344_CR8","doi-asserted-by":"crossref","unstructured":"Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG. Epidemiology of cutaneous leishmaniasis in Colombia: environmental and behavioral risk factors for infection, clinical manifestations, and pathogenicity. J Infect Dis. 1993 Sept;168(3):709\u201314.","DOI":"10.1093\/infdis\/168.3.709"},{"issue":"1","key":"12344_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4269\/ajtmh.1997.56.85","volume":"56","author":"CR Davies","year":"1997","unstructured":"Davies CR, Llanos-Cuentas EA, Campos P, Monge J, Villaseca P, Dye C. Cutaneous leishmaniasis in the Peruvian andes: risk factors identified from a village cohort study. Am J Trop Med Hyg. 1997;56(1):85\u201395.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"12344_CR10","doi-asserted-by":"publisher","first-page":"e0011818","DOI":"10.1371\/journal.pntd.0011818","volume":"17","author":"H Nuwangi","year":"2023","unstructured":"Nuwangi H, Agampodi TC, Price HP, Shepherd T, Weerakoon KG, Agampodi SB. Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review. PLoS Negl Trop Dis. 2023;17(12):e0011818.","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"12344_CR11","doi-asserted-by":"publisher","first-page":"e0006986","DOI":"10.1371\/journal.pntd.0006986","volume":"12","author":"A Uribe-Restrepo","year":"2018","unstructured":"Uribe-Restrepo A, Cossio A, Desai MM, D\u00e1valos D, Castro MDM. Interventions to treat cutaneous leishmaniasis in children: A systematic review. PLoS Negl Trop Dis. 2018;12(12):e0006986.","journal-title":"PLoS Negl Trop Dis"},{"key":"12344_CR12","unstructured":"Pan American Health Organization, Pan American Health Organization. Guideline for the Treatment of Leishmaniasis in the Americas. Second Edition. 2022; Available from: https:\/\/iris.paho.org\/handle\/10665.2\/56120"},{"issue":"9","key":"12344_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/cid\/civ004","volume":"60","author":"B Monge-Maillo","year":"2015","unstructured":"Monge-Maillo B, L\u00f3pez-V\u00e9lez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60(9):1398\u2013404.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"12","key":"12344_CR14","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","volume":"4","author":"PR Machado","year":"2010","unstructured":"Machado PR, Ampuero J, Guimar\u00e3es LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania Braziliensis in brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"12344_CR15","doi-asserted-by":"publisher","first-page":"e0011029","DOI":"10.1371\/journal.pntd.0011029","volume":"17","author":"MDM Castro","year":"2023","unstructured":"Castro MDM, Rode J, Machado PRL, Llanos-Cuentas A, Hueb M, Cota G, et al. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study. PLoS Negl Trop Dis. 2023;17(1):e0011029.","journal-title":"PLoS Negl Trop Dis"},{"key":"12344_CR16","doi-asserted-by":"crossref","unstructured":"Castro MDM, Gomez MA, Kip AE, Cossio A, Ortiz E, Navas A et al. Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis. Antimicrob Agents Chemother. 2017;61(3).","DOI":"10.1128\/AAC.02198-16"},{"issue":"8","key":"12344_CR17","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/jac\/dky143","volume":"73","author":"AE Kip","year":"2018","unstructured":"Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, et al. Simultaneous population Pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in new world cutaneous leishmaniasis and exploration of exposure-response relationships. J Antimicrob Chemother. 2018;73(8):2104\u201311.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"12344_CR18","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1093\/cid\/ciw670","volume":"63","author":"N Aronson","year":"2016","unstructured":"Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH). Clin Infect Dis. 2016;63(12):e202\u201364.","journal-title":"Clin Infect Dis"},{"issue":"3\u20134","key":"12344_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","volume":"64","author":"R Palacios","year":"2001","unstructured":"Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of Meglumine antimonate for cutaneous leishmaniasis due to leishmania Viannia species. Am J Trop Med Hyg. 2001;64(3\u20134):187\u201393.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"12344_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/infdis\/jir816","volume":"205","author":"LC Rubiano","year":"2012","unstructured":"Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodr\u00edguez-Barraquer I, Garcerant D, et al. Noninferiority of miltefosine versus Meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis. 2012;205(4):684\u201392.","journal-title":"J Infect Dis"},{"issue":"4","key":"12344_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4269\/ajtmh.19-0531","volume":"102","author":"C Suprien","year":"2020","unstructured":"Suprien C, Rocha PN, Teixeira M, Carvalho LP, Guimar\u00e3es LH, Bonvoisin T, et al. Clinical presentation and response to therapy in children with cutaneous leishmaniasis. Am J Trop Med Hyg. 2020;102(4):777\u201381.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"12344_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1086\/524042","volume":"46","author":"A Llanos-Cuentas","year":"2008","unstructured":"Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;46(2):223\u201331.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"12344_CR23","unstructured":"Ministerio de Salud del Per\u00fa. Leishmaniasis: M\u00f3dulos t\u00e9cnicos. Lima: MINSA [Internet]. 2000. Available from: https:\/\/www.gob.pe\/institucion\/minsa\/informes-publicaciones\/322303-leishmaniasis-modulos-tecnicos"},{"issue":"8","key":"12344_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","volume":"25","author":"M Solomon","year":"2011","unstructured":"Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to leishmania tropica. J Eur Acad Dermatol Venereol JEADV. 2011;25(8):973\u20137.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"5","key":"12344_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","volume":"83","author":"G Wortmann","year":"2010","unstructured":"Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(5):1028\u201333.","journal-title":"Am J Trop Med Hyg"},{"key":"12344_CR26","doi-asserted-by":"crossref","unstructured":"Hamill RJ, Amphotericin. B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 June;73(9):919\u201334.","DOI":"10.1007\/s40265-013-0069-4"},{"issue":"3","key":"12344_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1468-3083.2011.04070.x","volume":"26","author":"JOC Motta","year":"2012","unstructured":"Motta JOC, Sampaio RNR. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol JEADV. 2012;26(3):331\u20135.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"11","key":"12344_CR28","doi-asserted-by":"publisher","first-page":"e0006094","DOI":"10.1371\/journal.pntd.0006094","volume":"11","author":"R Guery","year":"2017","unstructured":"Guery R, Henry B, Martin-Blondel G, Rouzaud C, Cordoliani F, Harms G, et al. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea. PLoS Negl Trop Dis. 2017;11(11):e0006094.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"12344_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jaad.2012.06.014","volume":"68","author":"M Solomon","year":"2013","unstructured":"Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for leishmania Braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol. 2013;68(2):284\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"12344_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4269\/ajtmh.18-0514","volume":"102","author":"MC Rodr\u00edguez Galvis","year":"2020","unstructured":"Rodr\u00edguez Galvis MC, P\u00e9rez Franco JE, Casas Vargas MY, Ordo\u00f1ez Rubiano MF. Effectiveness and safety of amphotericin B Deoxycholate, amphotericin B colloidal Dispersion, and liposomal amphotericin B as Third-Line treatments for cutaneous and mucocutaneous leishmaniasis: A retrospective study. Am J Trop Med Hyg. 2020;102(2):274\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"12344_CR31","doi-asserted-by":"crossref","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003 July 1;13(3):176\u201381.","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"12344_CR32","doi-asserted-by":"crossref","unstructured":"Musa AM, Khalil EAG, Mahgoub FA, Hamad S, Elkadaru AMY, El Hassan AM. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005 Sept;99(6):563\u20139.","DOI":"10.1179\/136485905X514127"},{"key":"12344_CR33","doi-asserted-by":"crossref","unstructured":"Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC, Chung HY, et al. Paving the way for affordable and equitable liposomal amphotericin B access worldwide. Lancet Glob Health. 2024 Sept;12(9):e1552\u20139.","DOI":"10.1016\/S2214-109X(24)00225-0"},{"issue":"11","key":"12344_CR34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1046\/j.1365-4362.1998.00478.x","volume":"37","author":"MP Oliveira-Neto","year":"1998","unstructured":"Oliveira-Neto MP, Mattos M, Souza CS, Fernandes O, Pirmez C. Leishmaniasis recidiva cutis in new world cutaneous leishmaniasis. Int J Dermatol. 1998;37(11):846\u20139.","journal-title":"Int J Dermatol"},{"issue":"2","key":"12344_CR35","first-page":"138","volume":"30","author":"S Gallo Echeverri","year":"2022","unstructured":"Gallo Echeverri S, Galvis Franco W, Jaramillo Ayerbe F, Van den Enden L. Leishmaniasis cut\u00e1nea cr\u00f3nica En El Nuevo mundo: Serie de Casos de Otra Gran simuladora. AsoColDerma Rev Asoc Colomb Dermatol Cir Dermatol\u00f3gica. 2022;30(2):138\u201347.","journal-title":"AsoColDerma Rev Asoc Colomb Dermatol Cir Dermatol\u00f3gica"},{"issue":"10","key":"12344_CR36","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.clinthera.2021.09.011","volume":"43","author":"T Scardina","year":"2021","unstructured":"Scardina T, Fawcett AJ, Patel SJ. Amphotericin-Associated Infusion-Related reactions: A narrative review of Pre-Medications. Clin Ther. 2021;43(10):1689\u2013704.","journal-title":"Clin Ther"},{"issue":"2","key":"12344_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1086\/516321","volume":"26","author":"A Pathak","year":"1998","unstructured":"Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis Off Publ Infect Dis Soc Am. 1998;26(2):334\u20138.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"8","key":"12344_CR38","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1086\/368312","volume":"36","author":"A Imhof","year":"2003","unstructured":"Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;36(8):943\u201351.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"10","key":"12344_CR39","doi-asserted-by":"publisher","first-page":"e77075","DOI":"10.1371\/journal.pone.0077075","volume":"8","author":"ME Falagas","year":"2013","unstructured":"Falagas ME, Karageorgopoulos DE, Tansarli GS. Continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis. PLoS ONE. 2013;8(10):e77075.","journal-title":"PLoS ONE"},{"key":"12344_CR40","doi-asserted-by":"crossref","unstructured":"Autmizguine J, Guptill JT, Cohen-Wolkowiez M, Benjamin DKJ, Capparelli EV. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs. 2014 June;74(8):891\u2013909.","DOI":"10.1007\/s40265-014-0227-3"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12344-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:48:13Z","timestamp":1769168893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12344-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12344"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12344-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Institutional Review Board (IRB) of Hospital Cayetano Heredia. The IRB waived the requirement for informed consent for the use of clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}